Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Abu Dhabi National Oil Company (ADNOC) signed a deal with Exxon to buy a 35% share of a new hydrogen plant just outside Houston, Texas.
Data from two promising vaccine trials heralded potential breakthroughs in the treatment of pneumococcal infection and Lyme disease.
Early data this year suggests back-to-school season spending is either flat from last year, or took a slight dip.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Uber announced it’s investing in Wayve, a UK-based startup that’s building self-driving software for cars.
Danish company Lego reported generating $4.65 billion in revenue for the first half of 2024, up 13% from a year earlier.
A couple of China-based EV giants had good news to share in spite of a weakened consumer at home and fresh tariffs from the EU and Canada.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
ExxonMobil forecast that oil demand will remain above 100 million barrels per day in 2050, roughly the same as current levels.
The tech aims to walk a fine line of not overloading customers with bad ads as several streamers launch their own ad-supported tiers.
In addition to offering mobile headquarters for families on vacation, recreational vehicle sales are a pretty good indicator of the economy.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.